Abbott Laboratories stock: Leerink upgrades rating to Outperform
Published on 11/20/2026 at 16:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst Upgrade Adds Fresh Support
- Leerink Partners raised its Abbott Laboratories rating from Market Perform to Outperform on November 19.
- Abbott's business spans pharmaceuticals, diagnostics, nutrition and medical devices.
- The company is also advancing the Encantor TAVI system through the VOYAGER clinical trial.
Leerink Partners upgraded Abbott Laboratories from Market Perform to Outperform on Thursday, November 19, according to Fintel. The move gives investors a new analyst signal after Abbott's recent quarterly outlook reduction and a series of cardiovascular device developments.
Fintel's account identifies the prior rating as Market Perform and the new recommendation as Outperform. It also lists earlier actions from Argus Research, Wells Fargo, JPMorgan, RBC Capital Markets and Baird, but those actions predate the Leerink change.
Cardiovascular Pipeline Remains In Focus
Abbott is developing healthcare products across established pharmaceuticals, diagnostics, nutrition and medical devices. The company said on November 19 that it had initiated the VOYAGER clinical trial for its investigational Encantor software-guided, balloon-expandable transcatheter aortic valve implantation system, according to the company's press-release page.
For investors, the rating change and the trial program point to two separate parts of the current Abbott narrative: near-term views on earnings and valuation, and longer-term commercial potential from new cardiovascular devices. Trial progress, regulatory decisions and eventual market access remain important milestones for that pipeline.
Abbott Laboratories stock traded at 95.46 euros on Lang & Schwarz at 16:30 CET on Friday, November 20, 2026, 0.10 percent below the Xetra close of Thursday, November 19. The quote was in euros and the Xetra close was 95.56 euros.
Abbott Laboratories stock at a glance
- Company: Abbott Laboratories
- ISIN: US0028241000
- Xetra ticker: ABL.DE
- Trading venue: Lang & Schwarz
- Quote: 95.46 euros at 16:30 CET on Friday, November 20, 2026
- Xetra close: 95.56 euros on Thursday, November 19, 2026
Investors can follow broader US market developments in the Current market reports.
